Latest Investment News

Santos Limited’s 2024 Annual Report reveals a 5% decline in production and a 9% drop in sales revenue, yet the company progresses its climate transition with key CCS projects and emissions reductions.

Santos Limited’s 2024 Annual Report reveals a 5% decline in production and a 9% drop in sales revenue, yet the company maintains strong profitability and advances key climate initiatives including the Moomba CCS project.

Santos Limited’s 2024 Annual Report reveals a 5% decline in production and a 9% drop in sales revenue, yet highlights significant progress in carbon capture and storage projects and emissions reduction targets.

Santos Limited's 2024 Annual Report reveals a 5% drop in production and a 9% fall in sales revenue, yet highlights significant progress in carbon capture and storage and emissions reduction efforts. The company remains committed to its net-zero targets and sustainable growth strategy.

Santos Limited's 2024 Annual Report reveals a 5% drop in production and a 9% decline in sales revenue, yet highlights significant progress in carbon capture and storage projects and emissions reduction targets.

Santos Limited's 2024 Annual Report reveals a 5% drop in production and a 9% fall in sales revenue, yet the company maintains strong profitability and advances key climate initiatives including the Moomba CCS project.

Santos Limited’s 2024 Annual Report reveals a 5% drop in production and a 9% decline in sales revenue, yet highlights significant progress in carbon capture and storage projects and emissions reduction targets.

Santos Limited's 2024 Annual Report reveals a 5% drop in production and a 9% decline in sales revenue, yet highlights progress in carbon capture and storage and emissions reduction. The company maintains a strong balance sheet while advancing its Climate Transition Action Plan.

Renegade Exploration reports significant discoveries of critical defence metals germanium and gallium at its Yukon Andrew Deposit, alongside promising gold-silver prospects, while progressing copper and cobalt projects in Queensland amid a tight cash position.

EVE Health Group has executed a binding agreement to acquire Australian biotech Nextract, targeting rapid-onset treatments in the $16 billion global erectile dysfunction and dysmenorrhea markets. The acquisition, supported by a $1.5 million capital raise and share consolidation, marks a strategic shift into regulated pharmaceutical channels.

DGR Global Limited reported steady progress in project generation and strategic investments during Q1 2025, while navigating ongoing legal challenges and securing a $23.5 million funding facility to support operations and refinancing.

RooLife Group reported a strategic quarter marked by the launch of its TikTok UK marketplace, expansion of its own health product range, and a significant capital raise backed by a key Chinese partner.